Sökning: WFRF:(Tsakonas Georgios)
> (2019) >
c-MET as a biomarke...
c-MET as a biomarker in patients with surgically resected non-small cell lung cancer
-
- Tsakonas, Georgios (författare)
- Karolinska Institutet
-
- Botling, Johan (författare)
- Uppsala universitet,Klinisk och experimentell patologi,Johan Botling
-
- Micke, Patrick (författare)
- Uppsala universitet,Klinisk och experimentell patologi,Patrick Micke
-
visa fler...
-
- Rivard, Chris (författare)
- Univ Colorado, Div Med Oncol, Anschutz Med Campus, Aurora, CO USA
-
- La Fleur, Linnea (författare)
- Uppsala universitet,Klinisk och experimentell patologi,Johan Botling
-
- Mattsson, Johanna Sofia Margareta, 1985- (författare)
- Uppsala universitet,Klinisk och experimentell patologi,Patrick Micke
-
- Boyle, Teresa (författare)
- Univ Colorado, Div Med Oncol, Anschutz Med Campus, Aurora, CO USA
-
- Hirsch, Fred R. (författare)
- Univ Colorado, Div Med Oncol, Anschutz Med Campus, Aurora, CO USA
-
- Ekman, Simon (författare)
- Karolinska Institutet
-
visa färre...
-
(creator_code:org_t)
- Elsevier, 2019
- 2019
- Engelska.
-
Ingår i: Lung Cancer. - : Elsevier. - 0169-5002 .- 1872-8332. ; 133, s. 69-74
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: c-MET protein overexpression has been proposed as a biomarker in non-small cell lung cancer (NSCLC), albeit its role in the clinical setting has not been firmly established yet. Patients and methods: We designed a retrospective cohort study, consisting of 725 patients with surgically removed NSCLC. Immunohistochemistry (IHC) was conducted in tissue microarrays (TMA) from lung tumors and healthy tissue. IHC staining was quantified using H-scores (range 0-300). Association between c-MET H-score and overall survival (OS) as well as progression-free survival (PFS) was explored. Results: c-MET H-score >= 20 had a significant positive impact on OS in the multivariate analysis in the whole study population, HR = 0.79 (95%CI: 0.64 - 0.97). The prognostic effect of c-MET H-score >= 20 was even stronger in patients who received adjuvant treatment with a HR = 0.61 (95% CI: 0.40 - 0.93). In the subgroup of adenocarcinoma and squamous cell carcinoma patients with stage IIA-IIIB disease, the prognostic impact of c-MET was significant in the univariate analysis (HR = 0.60, 95% CI: 0.43 - 0.83). Conclusion: c-MET H-score >= 20 is a positive prognostic biomarker for OS in early stage NSCLC. This benefit seems to be strongly correlated to adjuvant chemotherapy, therefore rendering c-MET H-score >= 20 a possible predictive biomarker for platinum-based adjuvant chemotherapy in early stage NSCLC.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Klinisk laboratoriemedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Clinical Laboratory Medicine (hsv//eng)
Nyckelord
- c-MET
- Lung cancer
- Biomarker
- OS
- PFS
- H-score
- Patologi
- Pathology
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas